Select Page
First Alzheimer’s Treatment by Biogen Approved by FDA

First Alzheimer’s Treatment by Biogen Approved by FDA

The U.S Food and Drug Administration (FDA) has approved Biogen’s aducanumab treatment for Alzheimer’s which aims to eliminate the sticky deposits of amyloid beta found in the brains of patients in the initial stages of the disease. In spite of controversy and...
Fennec Pharmaceuticals Resubmits NDA for PEDMARK™

Fennec Pharmaceuticals Resubmits NDA for PEDMARK™

Fennec Pharmaceuticals has resubmitted their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™, a unique sodium thiosulfate formulation. PEDMARK is designed to prevent ototoxicity caused by cisplatin chemotherapy in patients under...